Regeneration

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Monday, July 11, 2022
Safety, PI, FDA, COVID-19, American Cancer Society, Adult, Skin cancer, Development, European Medicines Agency, Contract, Form 20-F, BCC, Food and Drug Administration Amendments Act of 2007, Basal-cell carcinoma, Annual report, Food, Burn, Squamous cell carcinoma, Company, Government, Life expectancy, Regeneration, Debridement, Cancer, Technology, Bromelain (pharmacology), Review, BARDA, Phrase, GLOBE, Patient, Research, Phase, Epidermis, Growth, Union, Pharmaceutical industry, Medical imaging, Medical device

YAVNE, Israel, July 11, 2022 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced positive initial data from eleven patients in its ongoing open-label Phase I/II study of MW005 for the treatment of low-risk Basal Cell Carcinoma (BCC). The initial data shows MW005 to be safe and well-tolerated, with a majority of the patients who completed the study achieving complete histological clearance of their target lesions following treatment with MW005. The Company anticipates announcing the final data in the second half of 2022.

Key Points: 
  • The initial data shows MW005 to be safe and well-tolerated, with a majority of the patients who completed the study achieving complete histological clearance of their target lesions following treatment with MW005.
  • At the end of eight weeks post treatment period, all patients undergo complete excision, and the specimen is subject to an independent histological clearance examination.
  • The data continues to validate our technology, providing us with multiple strategic alternatives to advance the development of this asset.
  • The data is in line with the previously published clinical experience we had and provides further clinical proof-of-concept.

Smith+Nephew introduces smart glasses into the operating room to enable remote technical support for UK surgeons during procedures

Retrieved on: 
Monday, July 11, 2022
Smith & Nephew, Partnership, LinkedIn, Instagram, Phrase, ENT, CEO, MIS, LSE, Unlimited, United States patent law, Form 20-F, Annual report, Kit, NYSE, Patent, NHS, FTSE100, Failure, Surgeon, OR, Forward-looking statement, Regeneration, Sports medicine, Longevity, Group, U.S. Securities and Exchange Commission, SNN, Technology, Patient, Twitter, Cone, Patient safety, Minimally invasive procedure, Medtech, Efficiency, Rod, United States Patent and Trademark Office, Medical device, Silviculture, Pharmaceutical industry, COVID-19, Facebook

By providing customers with smart surgery glasses, Smith+Nephew representatives can 'see' through the eyes of the surgeon, instrumentalist nurse, or any healthcare professional using them,enabling continuous remote support before, during, and after surgical interventions.

Key Points: 
  • By providing customers with smart surgery glasses, Smith+Nephew representatives can 'see' through the eyes of the surgeon, instrumentalist nurse, or any healthcare professional using them,enabling continuous remote support before, during, and after surgical interventions.
  • "This new partnership will enable our team to deliver the highest possible expertise exactly when our customers and patients need it.
  • At the same time, I believe enhancing our ability to support our customers remotely serves patient safety and sustainability to great effect."
  • The multi-year agreement with Rods&Cones allows Smith+Nephew to scale its remote support capability for customers, enabling connectivity with specialist surgeons during minimally invasive surgery.

MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

Retrieved on: 
Friday, July 8, 2022
Review, FDA, Patient, European Medicines Agency, Research, Form 20-F, Burn, GLOBE, COVID-19, Growth, Union, U.S. Securities and Exchange Commission, Phrase, Annual report, Regeneration, Bromelain (pharmacology), Development, Debridement, Food, Contract, SEC, BARDA, Government, Food and Drug Administration Amendments Act of 2007, Safety, Interest, Security (finance), Pharmaceutical industry, Medical device, Hospital

Dr. Snyder will present an analysis of the wound care market and the potential for EscharEx use based on the recent study data.

Key Points: 
  • Dr. Snyder will present an analysis of the wound care market and the potential for EscharEx use based on the recent study data.
  • The Advanced Wound Care Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients.
  • EscharEx is a bioactive therapy for debridement of chronic and other hard-to-heal wounds in advanced stages of clinical development.
  • Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.

NEXUS ROBOTICS RECEIVES $2.6 MILLION IN GRANT FUNDING FROM SUSTAINABLE DEVELOPMENT TECHNOLOGY CANADA (SDTC)

Retrieved on: 
Thursday, July 7, 2022
Nexus, CEO, Climate change, ESG, Multimedia, Regeneration, Sustainable Development Technology Canada, Plant, Robotics, Technology, Software, Machine learning, Artificial intelligence, Human, AI, Farmer, Freedom, Algorithm, Renewable energy, Agriculture, QC

Using a very unique combination of articulated arms, Artificial Intelligence and advanced algorithms to remove weeds and treat diseased plants, Nexus Robotics' self-driving robots help increase crop yield.

Key Points: 
  • Using a very unique combination of articulated arms, Artificial Intelligence and advanced algorithms to remove weeds and treat diseased plants, Nexus Robotics' self-driving robots help increase crop yield.
  • Nexus Robotics will attend and showcase its robot at the 2022 FIRA-USA convention in Fresno, CA from October 18th to 20th, 2022.
  • About Nexus Robotics Nexus Robotics is an agricultural technology solutions company that delivers flexibility and freedom to create the future of farming.
  • nexusrobotics.ca
    About Sustainable Development Technology Canada At SDTC, we support companies attempting to do extraordinary things.

New Study shows Urolithin A (Mitopure®) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis

Retrieved on: 
Thursday, July 7, 2022
Research, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Cell, Recycling, FDA, Scripps Research, Ageing, Patient, Knee, CEO, Research, Tissue, OA, Molecular medicine, DOI, Nature Medicine, Pomegranate, Multimedia, Cartilage, Osteoarthritis, Swiss Federal Institute of Technology, Swiss Federal Institute of Aquatic Science and Technology, Food, Inflammation, EPFL, Regeneration, Mitophagy, Partnership, Mitochondrion, Organelle, D Grubu, UA, List of Nature Research journals, Quality of life, Paper, Invention, European Journal of Clinical Nutrition, Urolithin A, Solution, Human, GRAS, Aging Cell, Joint, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eating, JAMA Network Open, European Journal, Dietary supplement, Pharmaceutical industry

This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).

Key Points: 
  • This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).
  • View the full release here: https://www.businesswire.com/news/home/20220707005266/en/
    This study showed that treatment with Amazentis proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints.
  • Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations.
  • Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.

BONAIRE DESIGNATED AS A CULINARY CAPITAL BY WORLD FOOD TRAVEL ASSOCIATION

Retrieved on: 
Thursday, July 7, 2022
CEO, Capital, Technology, Travel, Architecture, Tourism, Map, History, Association, Haryana Tourism Corporation, Food, Regeneration, Wellness, Certification, YouTube, Economic development, WFTA, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015, Culture, Facebook, Instagram, Twitter, News, Table, Program, National park, Michelin

LONDON, July 7, 2022 /PRNewswire/ -- The World Food Travel Association (WFTA) has certified Bonaire as a Culinary Capital. Through this program, the WFTA, a non-profit organization recognized as the world's leading authority on food and beverage tourism, vets destinations based on their scores across five culinary criteria: culture, strategy, promotion, community and sustainability. The program was launched to give food lovers confidence to travel to new and unexpected food and beverage destinations by assessing, certifying, and promoting places that showcase their unique gastronomy and culinary culture to visitors. With dining offerings ranging from chefs' tables to food trucks, Bonaire is the second destination to be honored as a Culinary Capital.

Key Points: 
  • LONDON, July 7, 2022 /PRNewswire/ -- The World Food Travel Association (WFTA) has certified Bonaire as a Culinary Capital.
  • With dining offerings ranging from chefs' tables to food trucks, Bonaire is the second destination to be honored as a Culinary Capital.
  • "Now the rest of the world will begin to hear more about the fantastic food and beverage products and experiences that this destination offers."
  • The collaboration between both the island's public and private sectors, along with the support of Bonaire Hotel and Tourism Association (BONHATA), was instrumental in bringing this Culinary Capital certification process to fruition.

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

Retrieved on: 
Thursday, July 7, 2022
Review, FDA, Patient, Decision-making, Biopsy, European Medicines Agency, Protein, Research, Chemokine, Form 20-F, Trial of the century, Burn, GLOBE, Biomarker, Infection, COVID-19, Element, Growth, Union, U.S. Securities and Exchange Commission, Reactive oxygen species, Phrase, Lipid, Polysaccharide, Cytokine, Annual report, Inflammation, Regeneration, Bromelain (pharmacology), Ulcer, Organic acid, Development, Debridement, Bacteria, Food, Contract, Wound healing, EPS, BARDA, SEC, VLU, Incidence, DFU, Mouth ulcer, Government, Matrix metalloproteinase, Food and Drug Administration Amendments Act of 2007, Safety, Leg, Security (finance), Sewage, Pharmaceutical industry, Hospital, Medical imaging, Medical device, HNE

YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced positive results from its U.S. prospective, open-label, single-arm, Phase 2 pharmacology clinical study of EscharEx® for the debridement of lower leg ulcers.

Key Points: 
  • The study was designed to evaluate the clinical performance, safety and pharmacology effect of EscharEx in debridement of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).
  • The U.S. phase 2 pharmacology study was a prospective, open label, single-arm study, being conducted at three U.S. clinical sites.
  • The study evaluated the clinical performance, safety, and pharmacology effect of EscharEx in the debridement of lower leg ulcers (VLUs and DFUs).
  • The study evaluated the safety and efficacy of debridement as measured by incidence of, and time to complete debridement.

3D Cell Culture Technologies Global Market Report 2022: Industry Expected to Reach $4.71 Billion in 2026 at a CAGR of 18.5%. - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, Biotechnology, Cell, Yeast, FDA, Patient, Yale University, BioTek, Probability, Scaffolding, 3D, COVID-19, Gel, Growth, Application, Mycoplasma, Transplant, Regeneration, Organ transplantation, Bacteria, Technology, 2D, Health, Virus, Vitro, Government, User (computing), PCL, Cell culture, Tuff, 3D printing

The "3D Cell Culture Technologies Global Market Report 2022, By Type, By End Users, By Scaffold-based, By Scaffold-free, By Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "3D Cell Culture Technologies Global Market Report 2022, By Type, By End Users, By Scaffold-based, By Scaffold-free, By Application" report has been added to ResearchAndMarkets.com's offering.
  • The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market.
  • Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment.
  • Global 3D Cell Culture Technologies Forecast Market, 2021-2026F, 2031F, $ Billion

Introducing TORUS Eyewear

Retrieved on: 
Wednesday, July 6, 2022
Cosmos, Nejat, Aluminium, Cotton, Foundation, Regeneration, UVA, Technology, Name, UVB, HNW, Collection, Torus

With relationships spanning from A-List celebrities, influencers and creators, to tech titans, and HNW luxury fashion connoisseurs, the founders expect to quickly establish TORUS as an exclusive, must-have premium eyewear brand.

Key Points: 
  • With relationships spanning from A-List celebrities, influencers and creators, to tech titans, and HNW luxury fashion connoisseurs, the founders expect to quickly establish TORUS as an exclusive, must-have premium eyewear brand.
  • The TORUS name and brand vision are inspired by the sacred geometric torus shape that charts the circular movement in every atom of the world, where all energies converge and then flow back into the universe.
  • As a sustainable brand, TORUS promises to push the world of eyewear outside of its comfort zone.
  • Always in search of innovation, Torus will push the boundaries of what is real and what is possible.

Innovative climate solutions are the focus of this year's RBC Tech for Nature 2022 funding partnerships

Retrieved on: 
Wednesday, July 6, 2022
Zero, Hive, ALDFG, Water, Recycling, Royal Bank of Canada, Artificial intelligence, Transport, CEO, Electric vehicle, Nature, Research, University, Carbon, Daily Hive, Climate change, Climate, Pembina Institute, Forest, Industry, Non-governmental organization, Organic, Kelp, Regeneration, Policy, Innovation, Plastic, Water supply, Natural Resources, Technology, Island, Solution, Farmer, Leadership, Biodiversity, RBC, Education, Seaweed, Renewable energy, Agriculture

RBC Tech for Nature is helping drive climate innovation and solutions in support of the transition to net zero, supporting more than 100 partner organizations conduct innovative research.

Key Points: 
  • RBC Tech for Nature is helping drive climate innovation and solutions in support of the transition to net zero, supporting more than 100 partner organizations conduct innovative research.
  • RBC Tech for Nature supports our climate strategy which outlines four key priority areas towards achieving net-zero by 2050.
  • "RBC Tech for Nature partners are developing solutions for a greener future and are working to get us all there faster."
  • 17 per cent of these projects focus on climate adaptation as we learn to live in a climate that is ever-changing.